A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
NCT06335303
Recruiting
This study is open to adults 40 years or older with idiopathic pulmonary fibrosis (IPF). People can join the study if they are not on any treatment for IPF are on stable treatment for at least 3 months before starting the study. The purpose of this study is to find out whether a medicine called BI 1819479 helps people with IPF. 3 different doses of BI 1819479 are tested in this study. Participants are put into 4 groups by chance. Participants in 3 groups get different doses of BI 1819479. Parti... Read More
Gender:
ALL
Ages:
40 years and above
Trial Updated:
04/29/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +164 locations
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates
Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment
NCT06411210
Recruiting
More than 40% of young adults with type 1 diabetes (T1D) also have overweight or obesity. Each of these diagnoses increase the risk of adverse cardiovascular events. GLP-1 analogues are anti-obesity medications that are cardioprotective in adults with type 2 diabetes, however evaluation of these agents in people with T1D has been limited to glycemic outcomes. Investigators aim to study the impact of GLP-1 analogue obesity treatment on markers of cardiometabolic risk in young adults with T1D and... Read More
Gender:
ALL
Ages:
Between 18 years and 30 years
Trial Updated:
04/29/2025
Locations: Yale Pediatric Diabetes Center, Adult and Children's Progam, New Haven, Connecticut
Conditions: Diabetes type1, Obesity
Register for Updates
A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)
NCT06450639
Recruiting
The purpose of this study is to assess the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of satralizumab, a humanized anti-interleukin-6 receptor (aIL-6R) monoclonal antibody, in ambulatory and non-ambulatory participants with DMD age ≥ 8 to \< 18 years old receiving corticosteroid therapy.
Gender:
MALE
Ages:
Between 8 years and 17 years
Trial Updated:
04/29/2025
Locations: Children's Healthcare of Atlanta Center for Advanced Pediatrics, Atlanta, Georgia +14 locations
Conditions: Duchenne Muscular Dystrophy
Register for Updates
A Phase 1 Study of SYNCAR-001 + STK-009 Without Conditioning Chemotherapy (Lymphodepletion) in Subjects With Severe, Refractory Systemic Autoimmune Rheumatic Disease
NCT06544330
Recruiting
This is a phase 1 study of SYNCAR-001 + STK-009 in patients with severe, refractory systemic autoimmune rheumatic disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/29/2025
Locations: HonorHealth Research Institute, Scottsdale, Arizona +4 locations
Conditions: Systemic Lupus Erythematosus, Lupus Nephritis, Systemic Sclerosis
Register for Updates
Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia
NCT06597019
Recruiting
This is a pivotal phase III study designed to evaluate safety, tolerability, and efficacy of inclisiran in children (aged 6 to \<12 years) with heterozygous familial hypercholesterolemia (HeFH) and elevated low density lipoprotein cholesterol (LDLC).
Gender:
ALL
Ages:
Between 6 years and 11 years
Trial Updated:
04/29/2025
Locations: UC San Francisco Medical Center, San Francisco, California +35 locations
Conditions: Familial Hypercholesterolemia - Heterozygous
Register for Updates
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
NCT06634589
Recruiting
The purpose of this study is to measure the safety, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics with BGB-16673 in combination with other agents in participants with relapsed or refractory (R/R) B-cell malignancies. This study is structured as a master protocol with separate substudies. This study currently includes four substudies, and more substudies may be added as other combination agents are identified.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/29/2025
Locations: Mayo Clinic Phoenix, Phoenix, Arizona +45 locations
Conditions: B-cell Malignancy, Relapsed Cancer, Refractory Cancer, B-cell Lymphoma
Register for Updates
A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
NCT06682806
Recruiting
This is a Phase 2 an open-label, multi-center study to determine the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and anti-tumor activity of PRT3789 in combination with pembrolizumab in patients with advanced, recurrent or metastatic solid tumors with a SMARCA4 mutation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/29/2025
Locations: Florida Cancer Specialists, West Palm Beach, Florida +5 locations
Conditions: Advanced Solid Tumor, Esophageal Cancer, Metastatic Solid Tumor, Non-small Cell Lung Cancers, SMARCA4 Gene Mutation
Register for Updates
A Study to Find Out How Litifilimab is Processed in the Body in Healthy Participants When Given Under the Skin in 3 Different Ways
NCT06741657
Recruiting
In this study, researchers will learn how the body processes litifilimab when it is given under the skin in 3 different ways. Currently, ongoing studies utilize pre-filled syringes (PFS) that can deliver litifilimab subcutaneously (SC), also known as under the skin. In this study, researchers want to learn more about new ways of delivering litifilimab SC using either an autoinjector (AI) or an on-body injector (OBI): Both devices are designed to deliver litifilimab in an automatic way, especia... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
04/29/2025
Locations: Las Vegas Clinical Research Unit, Las Vegas, Nevada +1 locations
Conditions: Healthy Volunteer
Register for Updates
Examining the Effects of Theta Burst TMS on Brain Connectivity and Balance Ability in Older Adults With Balance Problems
NCT06779188
Recruiting
The goal of this study is to learn if manipulating the brain using magnets works to treat balance impairment, a major cause of falls, in older adults with balance problems. The technique to manipulate the brain using magnets is known as transcranial magnetic stimulation or TMS. The main questions this study aims to answer are: * How does TMS change communication between brain areas? * Does TMS improve balance ability in older adults with balance problems? Researchers will compare the TMS group... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
04/29/2025
Locations: The Center for Neuromotor and Biomechanics Research at the University of Houston, Houston, Texas
Conditions: Aging, Balance Deficits
Register for Updates
Alcohol Labeling Study
NCT06835920
Recruiting
This study aims to examine the effects of new front-of-package alcohol warnings on alcohol consumption. Participants will be randomly assigned to either new front-of-package health warnings or control labels. Participants will bring in their own alcohol to weekly study visits and take home the alcohol to consume as usual. Participants will receive study labels on their alcohol containers per their assigned trial arm.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
04/29/2025
Locations: UNC study office, Chapel Hill, North Carolina +1 locations
Conditions: Health Behavior
Register for Updates
Dose Response of Exercise for Arthritis Management
NCT06880653
Recruiting
The purpose of the study is to see examine the effects of 3 different levels of physical activity (45 minutes/week, 90 minutes/week, or 150 minutes/week) on arthritis symptoms.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/29/2025
Locations: University of South Carolina, Columbia, South Carolina
Conditions: Arthritis, Rheumatoid Arthritis (RA), Gout, Fibromyalgia (FM), Osteoarthritis, Lupus Erythematosus, Systemic
Register for Updates
Effects of Natural Sourdough Fermentation Duration and Acid Development on Postprandial Blood Glucose in Prediabetic Adults
NCT06925451
Recruiting
The primary intervention for management of prediabetes is lifestyle changes. Eating healthier and increasing physical activity was found to slow the progression of prediabetes into diabetes, reduce the risk of other diseases like cardiovascular disease and hypertension, and have a lasting impact even after the intervention is discontinued. Studies found that increasing the intake of fiber, pre- and probiotics, and fermented foods have been linked to improved glycemic biomarkers. The goal of this... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/29/2025
Locations: 850 PBC, Phoenix, Arizona
Conditions: Insulin Resistance
Register for Updates